Mesenchymal stem cell labeling and in vitro MR characterization at 1.5 T of new SPIO contrast agent: Molday ION Rhodamine-B™.
In vivo detection of transplanted stem cells is requisite for improving stem cell-based treatments by developing a thorough understanding of their therapeutic mechanisms. MRI tracking of magnetically labeled cells is non-invasive and is suitable for longitudinal studies. Molday ION Rhodamine-B™ (MIRB) is a new superparamagnetic iron oxide (SPIO) contrast agent specifically formulated for cell labeling and is readily internalized by non-phagocytic cells. This investigation characterizes mesenchymal stem cell (MSC) labeling and MR imaging properties of this new SPIO agent. Effects of MIRB on MSC viability and differentiation as well as cellular loading properties were assessed for MSC labeled with MIRB at concentrations from 5 to 100 µg Fe/ml. Labeled MSC were evaluated, in vitro, on a clinical 1.5 T MRI. Optimal scanning sequences and imaging parameters were determined based on contrast-to-noise ratio and contrast modulation. Relaxation rates (1/T(2)*) for gradient-echo sequences were approximated and an idealized limit of detection was established. MIRB labeling did not affect MSC viability or the ability to differentiate into either bone or fat. Labeling efficiency was found to be approximately 95% for labeling concentrations at or above 20 µg Fe/ml. Average MIRB per MSC ranged from 0.7 pg Fe for labeling MIRB concentration of 5 µg Fe/ml and asymptotically approached a value of 20-25 pg Fe/MSC as labeling concentration increased to 100 µg Fe/ml. MRI analysis of MIRB MSC revealed long echo time, gradient echo sequences to provide the most sensitivity. Limit of detection for gradient echo sequences was determined to be less than 1000 MSC, with approximately 15 pg Fe/MSC (labeled at 20 µg Fe/ml). These investigations have laid the groundwork and established feasibility for the use of this contrast agent for in vivo MRI detection of MSC. Properties evaluated in this study will be used as a reference for tracking labeled MSC for in vivo studies.
Addicott
Benjamin
B
Diabetes Research Institute, University of Miami School of Medicine, FL 33101, USA. btaddicott@med.miami.edu
Willman
Melissa
M
Rodriguez
Jose
J
Padgett
Kyle
K
Han
Dongmei
D
Berman
Dora
D
Hare
Joshua M
JM
Kenyon
Norma Sue
NS
D000818:Animals; D049109:Cell Proliferation; D002470:Cell Survival / Q000235:genetics; D058948:Cell Tracking / Q000379:methods*; D002478:Cells, Cultured; D003287:Contrast Media / Q000737:chemistry / Q000493:pharmacokinetics*; D004526:Efficiency; D052203:Ferrosoferric Oxide / Q000737:chemistry / Q000493:pharmacokinetics*; D015870:Gene Expression; D008252:Macaca fascicularis; D008279:Magnetic Resonance Imaging / Q000379:methods*; D058185:Magnetite Nanoparticles / Q000737:chemistry; D059630:Mesenchymal Stem Cells / Q000166:cytology / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000502:physiology; D011859:Radiography; D012235:Rhodamines / Q000737:chemistry / Q000493:pharmacokinetics; D013194:Staining and Labeling / Q000379:methods*
D003287:Contrast Media; D058185:Magnetite Nanoparticles; D012235:Rhodamines; C029773:rhodamine B; D052203:Ferrosoferric Oxide